NCT01910571已完成1 期
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Number of participants with adverse events (single and multiple dose studies)
研究概览
简要总结
- This is a single centre, phase I, randomized, double-blind, placebo-controlled, crossover, dose escalating study of P7435 using single and multiple doses, to be conducted in healthy male and female (Non child bearing) subjects having BMI between 19 to 40 kg/m2.
- The study will be conducted in 2 parts as follows: Part A will consist of the Single Ascending Dose (SAD) study and Part B will consist of the Multiple Ascending Dose (MAD) study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects who are willing and are able to provide a written informed consent to participate in the study
- •Adult male and female subjects aged between 18 and 60 (both inclusive) years old
- •Subjects with a BMI between 19 to 40 kg/m2
- •Subjects, who are healthy, as having no clinically significant abnormalities in medical history, physical examination, clinical laboratory test results (hematology, biochemistry and urinalysis), vital signs and 12-lead electrocardiogram (ECG). The clinical significance of any abnormal finding in these parameters is left to the judgment of the Investigator, in conjunction with the Sponsor's clinical leader prior to enrolment
- •Subjects who smoke less than 10 cigarettes per day and are able to refrain from smoking during confinement
- •Subjects with the ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, coke, chocolate, "power drinks") and grapefruit juice starting from 72 hrs prior to the first admission (confinement) and continuing throughout the study
- •Subjects who have a high probability for compliance with the study procedures including ability and willingness to swallow capsules during the study and allow withdrawing blood samples
- •Male subjects who are agreeable to use methods of contraception as specified in the protocol during the study and up to 30 days after the administration of the last dose of the study drug
- •Female subjects who are of non-child bearing potential defined as females who are either post menopausal [i.e. 1 year of natural (spontaneous) amenorrhea or break-through bleeding together with follicle stimulating hormone (FSH) confirmation of post-menopausal state at screening)] or surgically sterilized [hysterectomy, tubal occlusion, bilateral oophorectomy or bilateral salpingectomy]. FSH is required to document post-menopausal status in women <55 years of age or in women >55 with < 2 years since last menstrual period. FSH is not required for women >55 with >2 years since last menstrual period.
排除标准
- •Employees of the Sponsor, Clinical Research Organization (CRO) or clinical sites
- •Subjects in an acute disease state within 7 days before Day -1 of the study
- •Subjects with past or current diseases of any organ or system (such as, but not limited to, gastrointestinal, cardiac, renal, hepatic that is considered to be clinically significant by the Investigator, in conjunction with the Sponsor's clinical leader or subjects suffering from any condition that can affect the absorption, distribution, metabolism and excretion of orally administered medicines. Subjects with conditions such as non malignant skin diseases and childhood asthma can be included based on the Investigator's discretion and discussed with the Sponsor a priori)
- •Subjects with known congenital QTc prolongation or having QTcF value of >450 msec
- •Subjects with a history of sleep apnea, irregular sleep/wake cycle or working in night shifts
- •Subjects with a history of hypo/hyperthyroidism, (except those with thyroxin replacement and on stable dose since last 2 months) or repeated abnormal TSH values at screening or obesity of endocrine origin
- •Subjects with a history of anaphylaxis or angioedema, or other clinically important food or drug allergy
- •Subjects with known lactose intolerance and / or intolerance / allergy to any component of the diet, including milk, soy and the high fat breakfast proposed to be given during the study
- •Subjects with a history of mental handicap, psychiatric disorders including (but not limited to) eating disorders, seizures or significant head trauma
- •Subjects with a history of drug abuse, addiction or use of recreational drug
- •Subjects with a history of alcoholism for more than 2 years or consumption of more than 3 alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and during the study (one drink is equal to one unit of alcohol - one glass wine, half pint beer, one measure or ounce of spirit)
- •Subjects with a history of fainting from blood collections or vasovagal syncope
- •Subjects with prior exposure to P7435 or participation in any of the previous cohorts
- •Subjects with a positive serology for human immunodeficiency virus (HIV-1/2) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies
- •Subjects with positive findings in urine drug screen
- •Subjects with a positive finding in urine alcohol screen
- •Subjects who have participated in another clinical trial within 30 days prior to the first drug administration
- •Subjects who are consuming any prescription drugs (including, but not limited to, sedatives and steroids); herbal supplements (including, but not limited to, St. John's Extract); or any other drugs likely to cause pharmacokinetic interaction within 30 days or 5 half lives, before first drug administration whichever is longer. Subjects using any other over-the-counter drugs (with the exception of paracetamol/NSAIDs and multivitamins that may be allowed up to 3 and 7 days before admission to the clinic, respectively) within 14 days or 5 half lives, prior to the first drug administration. Subjects who have undergone any weight loss surgery or are taking weight loss medications (including alternate medicine products) within 90 days prior to first drug administration
- •Subjects following an unusual diet e.g. low caloric, low sodium, within 30 days prior to first drug administration
- •Subjects who have donated blood (i.e. 350 mL) within 90 days prior to first drug administration.
研究组 & 干预措施
P7435
Experimental
- In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.
- In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period.
干预措施: P7435 (Drug)
Placebo
Placebo Comparator
- In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.
- In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period.
干预措施: Placebo (Other)
结局指标
主要结局
Number of participants with adverse events (single and multiple dose studies)
时间窗: 12-14 Months
- To determine the safety and tolerability of single (Part A) and multiple (Part B) ascending doses of P7435 in healthy, overweight or obese subjects
次要结局
- Food Effect(12-14 Months)
- Change in Fasting plasma glucose(12- 14 Months)
- Area under the plasma concentration (AUC)(12- 14 Months)
- Time to peak plasma concentration (t-max)(12- 14 Months)
- Peak Plasma concentration (Cmax)(12- 14 Months)
- Change in Fasting serum lipids(12- 14 Month)
- Fat tolerance test(12- 14 month)
- Fasting serum insulin(12 - 14 months)
- Fasting serum C-peptide(12-14 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy SubjectsAsthmaNCT04772365Shanghai Hengrui Pharmaceutical Co., Ltd.52
已完成
1 期
AZD8529 Single Ascending Dose Study in Healthy Japanese SubjectsHealthyNCT00886756AstraZeneca48
终止
1 期
Escalating Single Dose Study of Epsi- Gam in Healthy Normal SubjectsAllergy and ImmunologyNCT02559258Tunitas Therapeutics, Inc.5
已完成
1 期
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707Healthy ParticipantsNCT05068466Incyte Biosciences Japan GK30
Unknown
1 期
TQT2 Study to Evaluate the Effect of MD1003 on Cardiac Repolarization in Healthy Adult SubjectsHealthy VolunteersNCT04168723MedDay Pharmaceuticals SA64